PROZAC POSTS $493.9 MIL. IN THIRD QUARTER U.S. SALES; LILLY SEEKS TO EXPAND MARKET WITH ADOLESCENT DATA; SMITHKLINE PAXIL NINE-MONTH U.S. SALES ARE $477.4 MIL.
Executive Summary
Lilly is looking to adolescents to maintain the vigor in its maturing Prozac franchise. The company is planning to file with FDA for labeling changes to include data on the use of the antidepressant in patients under the age of 18, the company said.